Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 6
Submit an article Journal homepage
172
Views
2
CrossRef citations to date
0
Altmetric
Review

Vaccines for the prevention of respiratory viral infections: problems and current status

Wieslawa Olszewska Department of Respiratory Medicine, Wright Fleming Institute for Infection and Immunity, National Heart and Lung Division, Faculty of Medicine, Imperial College, St. Mary’s Campus, Paddington, London W2 1PG, UK. [email protected]
,
Rebecca Helson Department of Respiratory Medicine, Wright Fleming Institute for Infection and Immunity, National Heart and Lung Division, Faculty of Medicine, Imperial College, St. Mary’s Campus, Paddington, London W2 1PG, UK. [email protected]
&
Peter JM Openshaw Department of Respiratory Medicine, Wright Fleming Institute for Infection and Immunity, National Heart and Lung Division, Faculty of Medicine, Imperial College, St. Mary’s Campus, Paddington, London W2 1PG, UK. [email protected]
Pages 681-689 | Published online: 24 Feb 2005

Bibliography

  • AYRES JG, NOAH ND, FLEMING DM: Incidence of episodes of acute asthma and acute bronchitis in general practice 1976–87. Br: J. Gen. Pract. (1993) 43:361–364.
  • BARDIN PG, FRAENKEL DJ, SANDERSON G et al.: Amplified rhinovirus colds in atopic subjects. Clin. Exp. Allergy(1994) 24:457–464.
  • FALSEY AR, WALSH EE: Respiratory syncytial virus infection in adults. Clin. Microbiol Rev (2000) 13:371–384.
  • DROSTEN C, GUNTHER S, PREISER W et al.: Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N EngL J. Med. (2003) 348:1967–1976.
  • FLEMING DM: The impact of three influenza epidemics on primary care in England and Wales. Pharinacoeconoinics (1996) 3\(Suppl. 9):38–45.
  • THOMPSON WW, SHAY DK, WEINTRAUB E et al: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 289:179–186.
  • GORSE GJ, OTTO EE, POWERS DC,CHAMBERS GW, EICKHOFF CS, NEWMAN FK: Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis. (1996) 173:285–290.
  • BELSHE RB, MENDELMAN PM, TREANOR J et al.: The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Eng]. J. Med (1998) 338:1405–1412.
  • HARPER SA, FUKUDA K, COX NJ, BRIDGES CB: Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recoinin. Rep. (2003) 52:1–8.
  • Influenza virus vaccine live intranasal-MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R. D. (2003) 4:312-319. ii.FREY S, POLAND G, PERCELL S, PODDA A: Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine (2003) 21:4234–4237.
  • PODDA A, DEL GIUDICE G: MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines (2003) 2:197–203.
  • COULTER A, WONG TY, DRANE D, BATES J, MACFARLAN R, COX J: Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. Vaccine (1998)16:1243–1253.
  • BEN YEHUDA A, JOSEPH A, ZEIRA E et al.: Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J. Med. Viral. (2003)69:560–567.
  • FAULKNER L, BUCHAN G, SLOBBE Let al.: Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection. Vaccine (2003) 21:932–939.
  • CAO M, SASAKI 0, YAMADA A, IMANISHI J: Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine (1992)10:238–242.
  • BEN AHMEIDA ET, GREGORIADIS G, POTTER CW, JENNINGS R: Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: Role in protection against influenza A in mice. Vaccine (1993) 11:1302–1309.
  • RIMMELZWAAN GE NIEUWKOOP N, BRANDENBURG A et al.: A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine (2000) 19:1180–1187.
  • RIMMELZWAAN GE BAARS M, VAN BEEK R et at Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralising serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Vaccine (1999) 17:2512–2516.
  • VOETEN JT, RIMMELZWAAN GE NIEUWKOOP NJ, LOVGREN-BENGTSSON K, OSTERHAUS AD: Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8 cytotoxic T lymphocytes. Vaccine (2000) 19:514–522.
  • ZURBRIGGEN R: Immunostimulating reconstituted influenza virosomes. Vaccine (2003) 21:921–924.
  • BRUHL P, KERSCHBAUM A, KISTNER 0, BARRETT N, DORNER F, GERENCER M: Humoral and cell-mediated immunity to vero cell-derived influenza vaccine. Vaccine (2000) 19:1149–1158.
  • KISTNER 0, BARRETT N, MUNDT W et al: [Development of a novel influenza vaccine derived from a continuous cell line]. ALTEX (2001) 18:50–54.
  • KISTNER 0, BARRETT PN, MUNDT W, REITER W, SCHOBER-BENDIXEN S, DORNER F: Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine (1998) 16:960–968.
  • •• An article describing novel technology of influenza vaccine production. Instead of traditional egg-based production, Vero cells are used.
  • PALACHE AM, MEDEMAJK: Influenza vaccine production constraints. Viral Vaccine Meeting Barcelona, Spain (2003).
  • NICHOLSON KG: Impact of influenzaand respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect (1996) 116:51–63.
  • KIM HW, CANCHOLA JG, BRANDT C et al.: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. .1. Epidemiol (1969) 89:422–434.
  • ••Key publication demonstrating augmentedlung disease in children vaccinated with formalin-inactivated RSV.
  • CROWE JE Jr, BUI PT, LONDON PTet al: Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine (1994) 12:691–699.
  • CROWE JE Jr, BUI PT, DAVIS AR, CHANOCK PM, MURPHY BR: A further attenuated derivative of a cold-passaged temperature- sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine (1994) 12:783–790.
  • KARRON RA, WRIGHT PF, CROWE JE Jr et al.: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. I Infect. Dis. (1997)176:1428–1436.
  • WRIGHT PF, KARRON RA, BELSHE RB et al.: Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. I Infect. Dis. (2000)182:1331–1342.
  • COLLINS PL, HILL MG, CAMARGO E, GROSFELD H, CHANOCK PM, MURPHY BR: Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA (1995) 92:11563–11567.
  • •A report describing the recovery of infectious recombinant respiratory syncytial virus from cDNA.
  • WHITEHEAD SS, FIRESTONE CY, KARRON RA et al: Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/ (1030)to RSV vaccine candidate cpts248/ 404 increases its attenuation and temperature sensitivity. Vim/. (1999) 73:871–877.
  • BUKREYEV A, WHITEHEAD SS, MURPHY BR, COLLINS PL: Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. I Vim/. (1997)71:8973–8982.
  • BUKREYEV A, CAMARGO E, COLLINS PL: Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene../. Vim/. (1996) 70:6634–6641.
  • MURPHY BR, SOTNIKOV A, PARADISO PR et al.: Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine (1989)7:533–540.
  • TRISTRAM DA, WELLIVER RC, MOHAR CK, HOGERMAN DA, HILDRETH SW, PARADISO P: Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. .1. Infect. Dis. (1993) 167:191–195.
  • PARADISO PR, HILDRETH SW, HOGERMAN DA et at.: Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr. Infect. Dis. 1 (1994) 13:792-798.
  • GROOTHUIS JR, KING SJ, HOGERMAN DA, PARADISO PR, SIMOES EA: Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. .1. Infect. Dis. (1998)177:467–469.
  • FALSEY AR, WALSH EE: Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine (1996)14:1214–1218.
  • POWER UF, PLOTNICKY GILQUIN H, HUSS T et al.: Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology (1997) 230:155–166.
  • POWER UF, NGUYEN TN, RIETVELD E et al.: Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. I Infect. Dis. (2001) 184:1456–1460.
  • DONNELLY JJ, ULMER JB, LIU MA: DNA vaccines. Dev. Biol. Stand. (1998) 95:43–53.
  • ••Extensive overview of DNA vaccinevectors, immune responses induced by DNA vaccination, safety and further applications of DNA vaccine technology.
  • POLAND GA, MURRAY D, BONILLA-GUERRERO R: New vaccine development. Br. Med. .1. (2002) 324:1315-1319.
  • CROWE JE Jr: Current approaches to thedevelopment of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Vaccine (1995) 13:415–421.
  • TRIPP RA, MOORE D, JONES L, SULLENDER W, WINTER J, ANDERSON LJ: Respiratory Syncytial virus G and/or SH Protein alters Thl cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. Vim/. (1999) 73:7099–7107.
  • BEMBRIDGE GP, RODRIGUEZ N, GARCIA-BEATO R, NICOLSON C, MELERO JA, TAYLOR G: DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. Gen. Vim]. (2000) 10(Pt 81):2519–2523.
  • SCHMIDT AC, COUCH RB, GALASSO GJ et al.: Current research on respiratory viral infections: Third International Symposium. Antiviral Res. (2001) 50:157–196.
  • ••An extensive review coveringepidemiology, virology, pathogenesis, immunology and the prevention of respiratory viral infections.
  • REED G, JEWETT PH, THOMPSON J, TOLLEFSON S, WRIGHT PF: Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children 5 years old. Infect. Dis. (1997) 175:807–813.
  • LAURICHESSE H, DEDMAN D, WATSON JM, ZAMBON MC: Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997. Eur. .1 Epideiniol (1999) 15:475–484.
  • BELSHE RB, HISSOM FK: Cold adaptation of parainfluenza virus Type 3: induction of three phenotypic markers. .1. Med. Vim]. (1982) 10:235–242.
  • KARRON RA, WRIGHT PF, HALL SL et al.: A live attenuated bovine parainfluenza virus Type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. I Infect. Dis. (1995)171:1107–1114.
  • JONES T: PIV-3 vaccine National Institutes of Health/Aviron. Can: Opin. Investig. Drugs (2001) 2:890–892.
  • TAO T, DAVOODI F, CHO CJ et al: A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine (2000) 18:1359–1366.
  • TAO T, SKIADOPOULOS MH, DAVOODI F, SURMAN SR, COLLINS PL, MURPHY BR: Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone. Vaccine (2001) 19:3620–3631.
  • SKIADOPOULOS MH, SURMAN SR, RIGGS JM, ORVELL C, COLLINS PL, MURPHY BR: Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus Type 3 vectors expressing up to three foreign glycoproteins. Virology (2002) 297:136–152.
  • SCHMIDT AC, MCAULIFFE JM, MURPHY BR, COLLINS PL: Recombinant bovine/human parainfluenza virus Type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. Vim]. (2001) 75:4594–4603.
  • SKIADOPOULOS MH, SURMAN SR, RIGGS JM, COLLINS PL, MURPHY BR: A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J. Vim]. (2001) 75:10498–10504.
  • SHENK TE: Fkld Virology DM Knipe, PM Howley (Eds), Lippincott Williams & Wilkins (2001): 2265–2300.
  • OLSZEWSKA W, ZAMBON M, OPENSHAW PJ: Development of vaccines against common colds. Br. Med. Bull (2002) 62:99–111.
  • RYAN MA, GRAY GC, SMITH B, MCKEEHAN JA, HAWKSWORTH AW, MALASIG MD: Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults. Clio. Infect. Dis. (2002) 34:577–582.
  • Two fatal cases of adenovirus-related illness in previously healthy young adults-Illinois. MMWR Morb. Mortal. Wkly Rep. (2000) 50:553–555.
  • HENDLEY JO: Clinical virology of rhinoviruses. Adv. Virus Res. (1999) 54:453–466.
  • JOHNSTON S, PATTEM ORE PK, SMITH S et al.: The association of viral infections with longitudinal changes in respiratory symptoms and/or peak flow recordings in schoolchildren. Eur. Respir. .1. (1992)5:109s–429s.
  • SCHROECKENSTEIN DC, BUSSE WW: Viral 'bronchitis' in childhood: relationship to asthma and obstructive lung disease. Respir. Infect (1988) 3:40–48.
  • PAPADOPOULOS NG, BATES PJ, BARDIN PG et al.: Rhinoviruses infect the lower airways. Infect. Dis. (2000)181:1875–1884.
  • HAMORY BH, HAMPARIAN VV, CONANT RIVI, GWALTNEY JM Jr: Human responses to two decavalent rhinovirus vaccines. Infect. Dis. (1975)132:623–629.
  • FRANCIS MJ, HASTINGS GZ, SANGAR DV et al.: A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2.1 Gen. Vim]. (1987) 68:2687–2691.
  • PORTA C, SPALL VE, LINT, JOHNSON JE, LOMONOSSOFF GP: The development of cowpea mosaic virus as a potential source of novel vaccines. Intervirology (1996) 39:79–84.
  • VAN DEN HOOGEN BG, DE JONG JC, GROEN J et al.: A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. (2001) 7:719–724.
  • ••The first article describing the new humanmetapneumovirus.
  • BASTIEN N, NORMAND S,TAYLOR T et al.: Sequence analysis of the N, P, M and F genes of Canadian human metapneumovirus strains. Virus Res. (2003) 93:51–62.
  • GREENSILL J, McNAMARA PS, DOVE W, FLANAGAN B, SMYTH RL, HART CA: Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. Eineig. Infect. Dis. (2003) 9:372–375.
  • TANG RS, SCHICKLI JH, MacPHAIL Met al.: Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. Vim]. (2003) 77:10819–10828.
  • FOUCHIER RA, KUIKEN T, SCHUTTEN M et al.: Aetiology: Koch's postulates fulfilled for SARS virus. Nature (2003) 423:240.
  • ••A key publication, the SARS coronavirus isproved to be an aetiological factor of SARS.
  • NICHOLLS JM, POON LL, LEE KC et al.: Lung pathology of fatal severe acute respiratory syndrome. Lancet (2003) 361:1773–1778.
  • CHEN X, ZHOU B, LI M et al: Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J. Infect. Dis. (2004) 189:1158–1163.
  • YEH SH, WANG HY, TSAI CY et al.: Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution. Proc. Natl. Acad. Sci. USA (2004) 101:2542–2547.
  • CHINESE SARS MOLECULAR EPIDEMIOLOGY CONSORTIUM: Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science (2004)303:1666–1669.
  • RUAN YJ, WEI CL, EE AL et al.: Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet (2003) 361: 1779-1785.
  • TOBLER K, ACKERMANN M, GRIOT C: [SARS, possible zoonosis in the area of conflict of pathogenic coronaviruses of animals]. Schweiz. Arch. Tierheilkd. (2003)145:316–322.
  • NABEL GJ: Accelerated Vaccination for Ebola, SARS and Other Viruses. Viral Vaccine Meeting. Barcelona, Spain (2003).
  • THOMPSON WW, SHAY DK, WEINTRAUB E et al.: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 289:179–186.
  • FENDRICK AM, MONTO AS, NIGHTENGALE B, SARNES M: The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med. (2003) 163:487–494.
  • COOPER RJ, HOFFMAN JR, BARTLETT JG et al.: Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann. Intern. Med. (2001)134:509–517.
  • POOLE MD: A focus on acute sinusitis in adults: changes in disease management. Am. .1. Med. (1999) 106:38S–47S.
  • MELTZER MI, COX NJ, FUKUDA K: The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis. (1999)5:659-671. Website

Websites

  • http://www.rcgp-bru.demon.co.uk Weekly Returns Service website.
  • http:\\www.clevelandciriicmeded.com/ diseasemanagement/infectiousdisease/urti/ urti.htm MOSSAD-SB upper respiratory tract infections. The Cleveland Clinic Foundation (2002). Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.